Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatment
Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as
Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd.,
Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals